System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Martin Laimer is an expert in Dermatology at Paracelsus Medical University (Austria). As of October 2026, ScienceLeadR ranks Martin Laimer in the top 1% of experts worldwide for Skin Abnormalities, Congenital Abnormalities and Skin Diseases, Vesiculobullous. Martin Laimer has authored 246 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 1 of them ongoing. SLR score: 1,072 (community average: 125). How the SLR is computed.

LeadR Profile

Martin Laimer Paracelsus Medical University Austria
1 072 ScienceLeadR Reputation 1072

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Genetics - Biochemistry - Obstetrics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Paracelsus Medical University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 246

Citations

Citations: 8 275 1st author: 40 Last author: 49 Unique author: 5

Main journals

J Dtsch Dermatol Ges 27
Br J Dermatol 13
Hautarzt 10
J Eur Acad Dermatol Venereol 9
Obesity (Silver Spring) 8

Best Journals

J Clin Oncol 2
N Engl J Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
A Neutral Comparison of Multivariate Hypothesis Tests for Parallel Group Designs in Rare Disease Settings.
PMID 42768292 — sample size, rare diseases, multiple chronic conditions		Stat Med20260
Harnessing skin-resident γδ T cells for immunotherapy in cutaneous squamous cell carcinoma.
PMID 42341104 — skin, cells, carcinoma, squamous cell, neoplasms, immunotherapy, therapeutics, tissues, skin neoplasms, cutaneous squamous cell carcinoma		Sci Adv20260
Long-term cytokine exposure remodels the methylome and transcriptome of recessive dystrophic epidermolysis bullosa keratinocytes - a bioinformatic analysis.
PMID 42181678 — cytokines, skin, genes, epidermolysis bullosa dystrophica, transcriptome, neoplasms, interleukin-6, epidermolysis bullosa, keratinocytes, epigenome, therapeutics, gene expression		Front Cell Dev Biol20260
Meta-Analysis of Pain Management in Epidermolysis Bullosa.
PMID 41866785 — syphilis, pain, pain management, epidermolysis bullosa, dermatology		Br J Dermatol20260
Histo-Miner: Deep learning based tissue features extraction pipeline from H&E whole slide images of cutaneous squamous cell carcinoma.
PMID 41564120 — skin, cells, lymphocytes, carcinoma, squamous cell, melanoma, neoplasms, classification, granulocytes, deep learning, therapeutics, learning, tissues, landslides, computational biology, cutaneous squamous cell carcinoma		PLoS Comput Biol20260

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 4
Phase 2 2
N/A 1
Phase 1/Phase 2 1
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 6
Recruiting 3
Unknown 1

By type:

Interventional 10

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 3
multicentricup10 4

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum
2024-514306-31-00 — skin, safety, multiple chronic conditions, therapeutics, pyoderma, pyoderma gangrenosum		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS